Y-mabs announces completion of pre-bla meeting with fda for omburtamab

New york, feb. 11, 2022 (globe newswire) -- y-mabs therapeutics, inc. (the “company” or “y-mabs”) (nasdaq: ymab) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that it recently completed a pre-biologics license application (“pre-bla”) meeting with the u.s. food and drug administration (“fda”) regarding a potential pathway for fda approval of omburtamab for the treatment of patients with cns/leptomeningeal metastases from neuroblastoma. the company expects to resubmit the bla for omburtamab by the end of the first quarter 2022.
YMAB Ratings Summary
YMAB Quant Ranking